Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Pain
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Pain
    TopAbstracts in Pain 11/26/2009 - (DGNews)
    Chronic musculoskeletal pain and the occurrence of falls in an older population - (JAMA)
    Severe Joint Pain in Multiple Areas Associated With Increased Risk of Falls in Older Adults - (DGNews)
    TopAbstracts in Pain 11/19/2009 - (DGNews)
    FDA Approves Capsaicin 8% Patch for Treatment of Postherpetic Neuralgia - (DGNews)

    News archive

     Recent webcasts/CME - Pain
    • Practical Considerations in Management of Chronic Pain
    • Overview of Chronic Pain: Practical Definitions and Characteristics
    • Opioid Induced Constipation in Palliative Care : Consideration in the Care of a Unique Population
      Pain Management
      Revisiting Pain Management in Cancer Patients: Breakthrough Pain and its Treatments

      Webcasts/CME archive

       Recent cases - Pain
        A Patient with Neck Pain and Fever
        A Painful Red Eye
        A Patient with Osteoarthritis and Cardiovascular Disease Presenting with Bilateral Hip Pain: A Case Report
        Abdominal Pain Due to a Lost Guidewire: A Case Report
        Acute Abdominal Pain in a Patient Receiving Enoxaparin

        Cases archive
          




        my personal edition > pain > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Subcutaneous Methylnaltrexone Shows Efficacy for Opioid-Induced Constipation: Presented at ACG

          By Bruce Sylvester

          SAN DIEGO -- October 27, 2009 -- Patients with chronic nonmalignant pain experiencing opioid-induced constipation show significant improvements following treatment with subcutaneous (SC) methylnaltrexone, researchers stated here at the American College of Gastroenterology (ACG) 74th Annual Scientific Meeting.

          "Subcutaneous methylnaltrexone appears to be a highly-effective treatment for opioid-induced constipation," said presenter and investigator Evan Tzanis, Wyeth Research, Collegeville, Pennsylvania, on October 25.

          For the study, researchers randomised 469 patients (460 evaluable) to receive either daily methylnaltrexone SC (n = 150), every-other-day dosing (n = 148), or placebo (n = 162) for 4 weeks.

          Eligibility for the study included opioid dosing of >=50 mg oral morphine equivalents per day for >=2 weeks and <3 rescue-free bowel movements per week. Back pain (60%) was the most frequently reported pain condition.

          Potential patients with significant gastrointestinal or other medical disorders were excluded, as were those with a history of chronic constipation prior to opioid use or a history of alcohol or drug abuse within 1 year of screening.

          The researchers assessed symptoms using the Patient Assessment of Constipation-Symptoms (PAC-SYM) questionnaire at day 14 and day 28. They used standard statistical analyses to compare methylnaltrexone and placebo data.

          Results showed that at day 28, patients in the daily dosing group had achieved significant improvement compared with placebo for rectal symptoms (-0.56 vs -0.30; P < .05), stool symptoms (-0.76 vs -0.43; P < .001), and the global PAC-SYM scores (-0.62 vs -0.37; P < .001).

          Subjects in the every-other-day dosing group achieved significant improvement in stool symptoms (-0.69 vs -0.43; P < .05) and the global PAC-SYM scores (-0.52 vs -0.37; P < .05) compared with placebo.

          No significant differences appeared in abdominal symptom scores between either the once-daily group and placebo or the every other day group and placebo.

          Funding for this study was provided by Wyeth Research.

          [Presentation title: Effect of Methylnaltrexone SC on Constipation Symptoms Using the Patient Assessment of Constipation Symptoms (PAC-SYM) Questionnaire in Patients with Chronic Non-Malignant Pain and Opioid-Induced Constipation. Abstract 274]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send